Journal Mobile Options
Table of Contents
Vol. 16, No. 3, 2003
Issue release date: July 2003
Section title: Original Paper
Cerebrovasc Dis 2003;16:280–285

Annual Incidence of First Silent Stroke in the United States: A Preliminary Estimate

Leary M.C.a · Saver J.L.b
aDepartment of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass., and bUCLA Stroke Center and Department of Neurology, UCLA Medical Center, Los Angeles, Calif., USA.
email Corresponding Author

Megan C. Leary, MD

Division of Stroke and Cerebrovascular Disease, Department of Neurology

Palmer 125, Beth Israel Deaconess Medical Center

330 Brookline Avenue, Boston, MA 02215 (USA)

Tel. +1 617 632 8917, Fax +1 617 632 8920, E-Mail

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Recent estimates of stroke incidence in the US range from 760,000 to 780,000 annually, however these estimates do not reflect the incidence of silent infarcts and hemorrhages. Since population-based studies indicate the prevalence of silent stroke is substantially higher than that of symptomatic stroke, estimates of stroke incidence based solely on symptomatic events may substantially underestimate the annual stroke burden. Methods: The prevalence of silent infarcts for different age strata were abstracted from two US population-based MRI studies, the Atherosclerosis Risk in Communities Study and the Cardiovascular Health Study. Similarly, first silent cerebral hemorrhage incidence rates were derived from population-based MRI prevalence observations in the Austrian Stroke Prevention Study. Prevalence observations in these studies and death rates from the US Census were inputted to calculate age-specific first silent MRI infarct and hemorrhage incidence. Age- specific incidence rates were projected onto 1998 US population age cohorts to calculate the annual burden of first silent MRI ischemic stroke and first silent MRI cerebral hemorrhage. Results: Estimated age-specific annual incidence rates (per 100,000) of persons experiencing first silent MRI infarct ranged from 1,600 in the age 30–39 stratum to 16,400 at ages 75–79. Estimated incidence rates of first silent MRI cerebral hemorrhage ranged from 180 in the ages 30–39 to 6,900 at age >85. Overall, the projected annual incidence in 1998 of US individuals experiencing first silent MRI infarct was 9,040,000, and first silent MRI hemorrhage 1,940,000. Conclusions: In 1998, more than 11 million persons experienced stroke in the US, in whom approximately 770,000 were symptomatic and 11 million were first-ever silent MRI infarcts or hemorrhages. These findings demonstrate the incidence of stroke is substantially higher than suggested by estimates based solely on clinically manifest events.

© 2003 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/23/2002
Accepted: 10/24/2002
Published online: 7/18/2003

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 1

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information:

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.